Omeros Corporation Reports First Quarter 2011 Financi... (2011 issue of the Journal of Biological ...)

Omeros Corporation Reports First Quarter 2011 Financial Results

Date:5/10/2011

2011 issue of the Journal of Biological Chemistry.

Expanded its exclusive license to phosphodiesterase 7 (PDE7) inhibitors from Daiichi Sankyo Co., Ltd. to include the fields of addiction and compulsive disorders. Currently, Omeros is advancing PDE7 inhibitors for the treatment of these as well as movement disorders. Omeros is collaborating on this program with both the National Institute on Drug Abuse and The Michael J. Fox Foundation.

Announced the identification of compounds that interact selectively with two orphan GPCRs linked to pancreatic cancer (GPR182) and cognitive disorders (GPR12). Together with the three previously unlocked orphans linked to squamous cell carcinoma (GPR87), obesity (GPR85) and appetite control (GPR101), Omeros has now publicly announced that it has successfully unlocked five orphan GPCRs for drug development.

Reported positive results from the Phase 2b clinical trial evaluating OMS302 in patients undergoing cataract surgery. In this 221-patient study, subjects treated with OMS302 demonstrated statistically significant (p<0.0001) and clinically meaningful maintenance of mydriasis throughout the cataract procedure, and OMS302 significantly decreased (p=0.0418) pain in the early postoperative period and reduced the frequency of complaints of moderate and severe pain (2.5 times more complaints in the vehicle-treated patients). The product candidate was safe and well tolerated in this study.

Announced that OMS103HP failed to meet prespecified efficacy endpoints in a Phase 3 clinical program in patients undergoing arthroscopic anterior cruciate ligament reconstruction surgery. The data were confounded, and Omeros could not determine whether a drug effect was present in these trials.

About Omeros CorporationOmeros is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation, coagulopathies and disorders of the cen
'/>"/>

SOURCE Omeros Corporation
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4
Related medicine technology :

1. Omeros Announces Initiation of Patient Enrollment in OMS201 Phase 1 Study
2. Omeros Announces Publication of Clinical Results for OMS103HP in Arthroscopy: The Journal of Arthroscopic and Related Surgery
3. Omeros Announces Patient Enrollment in Phase 1/Phase 2 Study of OMS302
4. Omeros and The Parkinsons Institute and Clinical Center Enter into a Collaboration Agreement to Evaluate Novel Target for the Treatment of Movement Disorders
5. Omeros Receives $3.1 Million Milestone Payment from The Stanley Medical Research Institute for Schizophrenia Program
6. Omeros Prices Initial Public Offering of Common Stock at $10.00 Per Share
7. Omeros Announces National Institute on Drug Abuses Support for Phase 2 Clinical Study in Addiction Program
8. Omeros Corporation to Host Third Quarter 2009 Financial Results Conference Call on November 19
9. Daniel K. Spiegelman Elected to Board of Directors of Omeros
10. Omeros Reports Additional Phase 2 Data Showing Multiple Clinical Benefits In Patients Undergoing Meniscectomy Surgery
11. Omeros Selects Clinical Candidate for MASP-2 Program With Potential Applicability to Multiple Inflammatory Disorders

Post Your Comments:

(Date:5/23/2013)... BioElectronics Corporation (OTC Pink: BIEL), the maker of ... FDA panel meeting for non-thermal shortwave diathermy: ... Therapy Meeting was held on May 21, 2013 in ... of the meeting was very narrow, in that the ... the application of non-thermal shortwave diathermy for the treatment ...

(Date:5/23/2013)... Conn. , May 23, 2013 CAS Medical Systems, ... medical devices for non-invasive patient monitoring, today announced that ... Officer, will present at the 2 nd Annual Marcum ... Hyatt Hotel in New York City . ... p.m. ET in the Estate 10 room and will be ...

(Date:5/23/2013)... , May 23, 2013 Halozyme ... announced the appointment of David A. ... Ramsay was most recently Vice President, Corporate Development ... ) "With his established financial management ... gained by working in our commercial group for ...

Breaking Medicine Technology:BioElectronics and Pulsed Shortwave Therapy Make Progress 2 CASMED to Present at the 2nd Annual Marcum MicroCap Conference 2 Halozyme Therapeutics Names David A. Ramsay Chief Financial Officer 2

[0] BioElectronics and Pulsed Shortwave Therapy Make Progress [0] CASMED to Present at the 2nd Annual Marcum MicroCap Conference [0] Halozyme Therapeutics Names David A. Ramsay Chief Financial Officer

... May 21 Isis Pharmaceuticals, Inc. (Nasdaq: ISIS ), the leader ... Citi Investment Research,s 2010 Global Health Care Conference on Thursday, May 27, ... Hotel. , , , ... the presentation will be available on the "Investors & Media" section of the ...

... Sorrento Therapeutics, Inc. (OTC Bulletin Board: SRNE) ... Small Business Technology Transfer Research (STTR) grant from the ... grant was awarded to support the Company,s program to ... combat Staphylococcus aureus ( S. aureus ...

Cached Medicine Technology:Isis Pharmaceuticals to Present at the 2010 Citi Investment Research Global Health Care Conference 2 Sorrento Therapeutics Awarded NIH Grant for MRSA Program 2 Sorrento Therapeutics Awarded NIH Grant for MRSA Program 3 Sorrento Therapeutics Awarded NIH Grant for MRSA Program 4

Isis Pharmaceuticals to Present at the 2010 Citi Investment Research Global Health Care Conference Sorrento Therapeutics Awarded NIH Grant for MRSA Program

(Date:5/23/2013)... FL (PRWEB) May 23, 2013 ... regenerative medicine company focused on the commercialization of ... and regeneration, today announced that the Company and ... million grant, for which AxoGen’s portion is approximately ... administrated by the U.S. Department of Defense (DoD) ...

(Date:5/23/2013)... 2013 Hile Design LLC is pleased ... awarded a Silver Creative Award at the Summit International ... entry was for its “Open Doors” animation promoting Scio ... in the 2013 District 6 ADDY Awards for the ... Creative Award recognizes and celebrates the creative achievements of ...

(Date:5/23/2013)... Utah (PRWEB) May 23, 2013 Registered ... R.D., published an article today on Tatalou.com offering helpful ... vacation. , The article, titled “ How to Stay ... important to carry hand sanitizer, when it’s safe to ... out for seafood, the importance of staying hydrated and ...

(Date:5/23/2013)... OH and Durham, NC (PRWEB) May 23, 2013 ... and commercialization firm that funds and develops innovative ... Deep Brain Innovations, LLC (DBI). DBI will ... optimize deep brain stimulation (DBS) therapy for patients ... is effective in treating Parkinson’s disease and generates ...

(Date:5/23/2013)... Consortium, Ltd., issued the following statement today on ... Reform of chemical safety legislation will succeed only ... Ensuring the safety and appropriate use of chemicals ... Toxic Substances Control Act is a critical opportunity ... transforming toxicity testing "from a system based on ...

Breaking Medicine News(10 mins):Health News:AxoGen, Inc. Receives Grant in Partnership with Vanderbilt University from U.S. Department of Defense 2 Health News:AxoGen, Inc. Receives Grant in Partnership with Vanderbilt University from U.S. Department of Defense 3 Health News:How to Stay Healthy While Traveling 2 Health News:NDI Launches Deep Brain Innovations, LLC 2 Health News:NDI Launches Deep Brain Innovations, LLC 3

[0] AxoGen, Inc. Receives Grant in Partnership with Vanderbilt University from U.S. Department of Defense [0] Hile Design Wins Silver Creative Award at the 2013 Summit Internationals [0] How to Stay Healthy While Traveling [0] NDI Launches Deep Brain Innovations, LLC [0] Chemical Safety Improvement Act of 2013: PETA International Science Consortium

... global research,organization, announced that it has appointed new staff ... Resourcing Solutions,division. Maria Sanchez Garcia will lead the group ... whilst Hannah King joins our United,Kingdom team to focus ... very pleased to help in the continued growth of ...

... deal demonstrates commitment to dermatology and innovation, ... Stiefel Laboratories, Inc.,the world,s largest independent pharmaceutical ... has completed its previously announced,acquisition of Princeton, ... of the acquisition, all remaining outstanding shares ...

... Call and Webcast Scheduled for August 7, 2008 ... Aug. 6 The Ensign,Group, Inc. (Nasdaq: ... group of,skilled nursing, rehabilitative care services and assisted ... quarter of fiscal,year 2008., (Logo: http://www.newscom.com/cgi-bin/prnh/20071213/LATH168LOGO ...

... ... Diluted FAD ... Second Quarter Investments $250 Million, NEWPORT BEACH, Calif., ... operations,and investment activity for the second quarter and the six months ended,June 30, 2008., ...

... put themselves at increased risk for second malignancies , , ... British adults who survived childhood cancers currently smoke, while ... in their lives, a new study reports. , ... cancer have a greater chance of developing cardiovascular disease, ...

... Aug. 6 AMN Healthcare Services,Inc. (NYSE: AHS ... leader in all of its business segments today reported ... quarter last year and a 7%,increase from last quarter. ... Nurse & Allied, Locum Tenens and,Physician Permanent Placement, experienced ...

Chiltern's Resourcing Solutions Division Appoints New Managers to Spain and the United Kingdom Stiefel Laboratories Completes Acquisition of Barrier Therapeutics The Ensign Group, Inc. Reports Second Quarter 2008 Earnings of $.32 per Diluted Share and Raises 2008 Guidance NHP Reports Second Quarter 2008 Earnings One-Fifth of British Childhood Cancer Survivors Smoke AMN Healthcare Reports Second Quarter 2008 Results

... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...

... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...

... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...

Medicine Products:

Lyme Antibodies, Total (CSF)Luteinizing Hormone, Pooled Lupus Anticoagulant Panel with Reflex to 1:1 Mixes & Confirmations Lupus Erythematous, Tissue